Evolva Fact Sheet Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, vanilla, saffron and resveratrol. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. Evolva is listed on the Swiss Stock Exchange (ticker EVE) and has operations near Basel (Switzerland), in Chennai (India), Copenhagen (Denmark) and in the USA. Technology platform Evolva uses sophisticated biosynthetic and evolutionary technologies to create and optimise small molecule compounds and their production routes. Evolva’s technological approach is protected by a broad IP estate and includes multiple pending and granted patent families.   For food and consumer health products this capability is mainly used to establish fermentation production routes for already used ingredients. The focus is on ingredients where existing methods are insufficient (they are too expensive, too variable, too impure, too limited in scale, not sustainable, etc.). For pharmaceutical products the capability is mainly used to discover novel, functional compounds the production of which may then take place via chemical synthesis or fermentation. Questions about our fermentation approach? Have a look at our video Partnering Evolva is establishing multiple discovery and codevelopment collaborations with industry partners to develop new compounds and production methods in the pharma, healthcare and nutrition industries. We aim to partner our technologies and product pipeline with companies who have the resources and skills to conduct late stage product development and marketing. We adopt a business-to-business model where we share in the value of these products through a mixture of milestone, royalty and supply agreements with these partner companies. Basel  Cambridge  Management Evolva is led by a strong management team with a proven track record developing and leading biotechnology companies, supplemented with extensive pharma experience.  Neil Goldsmith, Managing Director & CEO, Co-founder. 24 year track record in building successful biotech companies from start-up.  Jakob Dynnes Hansen, Chief Financial Officer, Extensive experience in biotech and finance. Previously with Nuevolution, Zealand Pharma and Novo Nordisk.  Luc Gruner, Chief Sales & Marketing Officer, broad background in sales/ marketing, strategic planning and business development.  Jørgen Hansen, Chief Scientific Officer, Previously Head of Research at Evolva Denmark. Gathered broad experience in yeast genetics at Poalis and Carlsberg Laboratories.  Pascal Longchamp, Chief Business Officer, Over 15 year in biotech/pharma. Previously at Phyllom and Maxygen.  Panchapagesa Murali, Managing Director, Evolva India. Over 20 years in Pharmaceutical & Healthcare R&D, managed more than 10 clinical trials.  Simon Waddington, CEO of Evolva Nutrition, Inc. Has extensive experience in venture capital as well as in biotechnology, among others at Monsanto and Zeneca. Chennai  Copenhagen  San Francisco Product pipeline Product Vanilla Resveratrol Projected Launch   Progress 2014 to date Marketed by IFF Commercial production. Pre-launch activities Stevia 2015/16 Milestone payment. RebM patent published Saffron 2016 Pathway optimisation. Sensory work Agarwood > 2017 Partnership in Malaysia. Pathway creation Evolva’s resveratrol is a compound that has been shown to have beneficial effects against several health conditions related to ageing. It has selfaffirmed GRAS (Generally Regarded As Safe) status in the USA and Novel Foods authorisation in the EU for use in Dietary Supplements. In the Vanillin project, Evolva is working with USbased International Flavors & Fragrances (IFF). Commercial batches have been produced and IFF has started the launch process by presenting the material to flavorists and application teams. Evolva is working with US-based Cargill on a fermentation-based route to produce the steviol glycoside components of the natural sweetener Stevia. This process should allow production of pure Stevia sweetness components with compelling health, taste and other benefits. Saffron is the world’s most expensive spice, as well as one of the oldest. It comes from the stigma of the Saffron crocus and is used for food colouring and flavouring, as well as for its aroma properties. Evolva is optimising the production process in order to enable commercial production of the saffron components. The acquisition of Allylix in December 2014 further broadened Evolva’s pipeline. Evolva has collaboration agreements with:  IFF, a leading creator and manufacturer of flavours and fragrances for consumer products. Evolva works with IFF on the vanillin project, described above.  Cargill, a major international provider of food, agricultural and other products with 2013 revenues of USD 137 billion. Evolva and Cargill work together in the stevia project.  BASF, the world’s leading chemical company, to find biosynthetic routes for selected natural products with crop protection potential.  Roquette, a world leader in the area of nutrition and other products based on raw vegetable materials, to find new biosynthetic production routes for an important food ingredient.  Ajinomoto, a global manufacturer of seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. The project involves a natural ingredient for use in personal care products.  L’Oréal, widely recognised as a global leader and innovator in cosmetics, to develop novel biosynthetic production routes for an ingredient with broad applications in the cosmetics industry.  Takasago, a world leader in the flavour & fragrance industry, to develop biosynthetic production routes to several ingredients with broad application in the F&F industry. Apart from the projects in consumer healthcare and nutrition, listed above, Evolva has worked on several pharma programmes (EV-077 and EV-035) which have been outlicensed. In addition, Evolva is active in several research projects funded by national or EU institutions. Financials Evolva reported revenues of CHF 8.7m in 2013 (FY2012: CHF 7m). Cash per the end of June 2014 was CHF 61 million. For further information on Evolva and its activities, please visit www.evolva.com. Evolva Factsheet January 2015